Date of prep: December 2020
Prescribing information and
adverse events reporting
For healthcare professionals only
The Competitions and Marketing Authority (CMA) has announced the disqualification of pharmaceutical company director Amit Patel after he admitted his role in arrangements that broke competition law.
Amit Patel has signed undertakings that ban him from holding a director role at any UK company for the next five years, in connection with his involvement in illegal arrangements during his time at Auden McKenzie (Pharma Division) Ltd and Amilco Ltd.
From September 2014 to May 2015, Mr Patel was a director at the pharmaceutical company Auden McKenzie. A Competition and Markets Authority (CMA) investigation into agreements affecting the supply of nortriptyline, an NHS prescribed drug used by thousands of patients to relieve the symptoms of depression, found that Auden McKenzie and King Pharmaceuticals Ltd had shared out between them the supply of the drug to a large pharmaceutical wholesaler. The two companies agreed that King would supply only 25mg tablets and Auden Mckenzie only 10mg tablets. They also agreed to fix quantities and prices to the wholesaler.
The object of this agreement was to limit competition, meaning the NHS, and ultimately the taxpayer, could have been paying higher prices than if competition hadn’t been restricted by the agreement.
Mr Patel is currently the sole director at Amilco and has held this directorship since 2013. Mr Patel admitted that from 1 March 2016 to 19 Oct 2016, Amilco and another pharmaceutical company, Tiofarma, stayed out of the UK fludrocortisone market enabling the market-leader Aspen to maintain its position as the sole supplier for the UK. Fludrocortisone is a prescription-only medicine that patients rely on to treat primary or secondary adrenal insufficiency, commonly known as Addison’s Disease, and the CMA has alleged that this illegal agreement protected Aspen’s monopoly, giving it an opportunity to increase prices charged to the NHS by up to 1800%.
Mr Patel has now admitted that, in exchange for staying out of the market, Amilco received a 30% share of the increased prices that Aspen was able to charge.
Amit Patel will now be disqualified from taking up any director role or being involved in the management of any company based in England, Scotland or Wales for five years.
Consistent with his admission, Mr Patel has also withdrawn his appeal against the CMA’s nortriptyline decision.
Michael Grenfell, the CMA’s Executive Director of Enforcement, said:
“Company directors have a responsibility to make sure their companies comply with competition law. And the CMA is determined to protect the public from directors who fail to do so.
“Today’s action should act as a warning to those in management positions – the CMA will not stand by when your firms break the law and take advantage of customers.”
This article is being shared under the Open Government Copyright licence.
Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.